The development of the steroidal MR antagonists spironolactone and eplerenone led to convincing evidence from preclinical studies that MR blockade reduces tissue damage in various diseases, especially chronic kidney disease (99). The gene discussed is NR3C2; the disease is chronic kidney disease.